FDA Approves Talvey (talquetamab) for Relapsed Multiple Myeloma

Key Takeaways

• FDA approved Talvey (talquetamab) on October 17, 2023, for relapsed or refractory multiple myeloma.
• The TALQUETO trial (NCT05032950) demonstrated a 73% overall response rate with a median duration of response of 11.3 months.
• Common adverse events include cytokine release syndrome (57%) and neurotoxic events (11%), with most CRS cases being grade 1 or 2.
• Talvey targets GPRC5D on myeloma cells and CD3 on T cells, representing a new mechanism of action in multiple myeloma treatment.

What is the mechanism of action for Talvey?

Talvey targets GPRC5D, a receptor overexpressed in multiple myeloma cells, and CD3 on T cells, thereby enhancing T-cell-mediated cytotoxicity against myeloma cells. Janssen Pharmaceuticals developed this bispecific antibody.

Background on Multiple Myeloma Treatment

Multiple myeloma, a hematologic malignancy characterized by the proliferation of malignant plasma cells, presents a significant treatment challenge, especially in relapsed cases. Despite the availability of multiple therapies, the disease often becomes refractory, necessitating the development of innovative treatment approaches.

The approval of new bispecific antibodies like talquetamab provides clinicians with additional options for patients who have exhausted standard therapies. These therapies represent a shift toward targeting specific tumor antigens with precision immunotherapy.

Key Clinical Data from the TALQUETO Trial

The approval of Talvey is primarily based on data from the pivotal TALQUETO trial (NCT05032950), which evaluated the efficacy and safety of talquetamab in patients with relapsed or refractory multiple myeloma who had received at least two prior lines of therapy. The trial reported an overall response rate (ORR) of 73% (95% CI, 66-80) among the 138 evaluable patients, with a median duration of response (DOR) of 11.3 months.

In terms of safety, the most common adverse events (AEs) observed were cytokine release syndrome (CRS), which occurred in 57% of patients, and neurotoxic events, reported in 11%. Notably, most CRS cases were grade 1 or 2, indicating manageable toxicity profiles. These results underscore the potential of talquetamab to provide a new therapeutic option for patients who have become resistant to existing treatments.

Market Impact and Availability

Talvey is expected to fill a critical niche in treating relapsed multiple myeloma, addressing the needs of patients who have exhausted other therapies. The drug is anticipated to be commercially available in early 2024, with pricing and reimbursement strategies still under negotiation. Analysts predict that Talvey could capture a significant share of the market, given its unique mechanism and efficacy profile.

In terms of competition, talquetamab will enter a market already populated with therapies such as daratumumab and isatuximab, which are also used in relapsed multiple myeloma. However, the dual-targeting mechanism of talquetamab may provide a distinct advantage in patient outcomes, particularly in those with high-risk disease characteristics.

What is the clinical significance of this approval?

Key opinion leaders (KOLs) in the field have lauded the approval of talquetamab, emphasizing its importance in expanding treatment options for a challenging patient population. The approval represents a significant advancement in treating relapsed multiple myeloma, providing hope for patients who have limited options left. Future development plans for talquetamab include studies to evaluate its efficacy in combination with other therapies and its potential in earlier lines of treatment.

Frequently Asked Questions

What is Talvey (talquetamab)? Talvey is a GPRC5D-targeted bispecific antibody approved by the FDA on October 17, 2023, for treating relapsed or refractory multiple myeloma in patients who have received at least two prior lines of therapy. What is the mechanism of action for Talvey? Talvey binds to GPRC5D on multiple myeloma cells and CD3 on T cells, redirecting T cells to kill myeloma cells through bispecific T-cell engager technology. What were the results of the TALQUETO trial? The TALQUETO trial demonstrated a 73% overall response rate (ORR) with a 95% confidence interval of 66-80, and a median duration of response of 11.3 months among patients with relapsed or refractory multiple myeloma. What are the common side effects of Talvey? The most common side effects include cytokine release syndrome (CRS), occurring in 57% of patients, and neurotoxic events, reported in 11% of patients. Most CRS cases were grade 1 or 2. When did Talvey become available commercially? Talvey became commercially available in early 2024 following FDA approval in October 2023.

Primary Sources

1. U.S. Food and Drug Administration. FDA approval. Accessed 2026-03-30.
2. ClinicalTrials.gov. TALQUETO Study (NCT05032950). Accessed 2026-03-30.
3. Janssen Pharmaceuticals. Talvey (talquetamab) development. Accessed 2026-03-30.

Related Coverage

• GSK Blenrep wins FDA approval in relapsed multiple myeloma
• FDA Approves Lumasiran for PH1: What BD and Investors Should Know
• GSK's Blenrep returns to the US market after FDA approves resubmission